Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells
Open Access
- 1 August 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 29 (11) , 2175-2181
- https://doi.org/10.1093/carcin/bgn179
Abstract
DNA hypermethylation is a common epigenetic alteration in human prostate cancer and is considered to contribute to development of this disease. Accumulating data suggest that dietary factors may alter cancer risk by modifications of epigenetic processes in the cell. The present study was designed to investigate whether selenium (Se) would alter epigenetic events to regulate methylation-silenced genes in human prostate cancer cells. DNA methylation, histone modifications and gene expression were studied in LNCaP cells after selenite treatment using polymerase chain reaction, western blot analysis, chromatin immunoprecipitation assay and enzymatic activity assay. Our study shows that selenite treatment caused partial promoter DNA demethylation and reexpression of the π-class glutathione- S -transferase ( GSTP1 ) in LNCaP cells in a dose- and time-dependent manner. Selenite treatment decreased messenger RNA levels of DNA methyltransferases (DNMTs) 1 and 3A and protein levels of DNMT1. Selenite also decreased histone deacetylase activity and increased levels of acetylated lysine 9 on histone H3 (H3-Lys 9), but decreased levels of methylated H3-Lys 9. Selenite treatment reduced levels of DNMT1 and methylated H3-Lys 9 associated with the GSTP1 promoter, but increased levels of acetylated H3-Lys 9 associated with this promoter. Additionally, selenite treatment decreased general DNA methylation and caused partial promoter demethylation and reexpression of the tumor suppressor adenomatous polyposis coli and cellular stress response 1, a gene involving tumor growth and metastasis. Our study demonstrates that Se can epigenetically modulate DNA and histones to activate methylation-silenced genes. These epigenetic modifications may contribute to cancer prevention by Se.Keywords
This publication has 38 references indexed in Scilit:
- Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer TherapyThe Cancer Journal, 2007
- Abnormal DNA methylation, epigenetics, and prostate cancerFrontiers in Bioscience-Landmark, 2007
- CSR1 Suppresses Tumor Growth and Metastasis of Prostate CancerThe American Journal of Pathology, 2006
- Chemoprevention of Prostate CancerAnnual Review of Medicine, 2006
- DNA methylation and histone modifications: teaming up to silence genesCurrent Opinion in Genetics & Development, 2005
- Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and TreatmentJNCI Journal of the National Cancer Institute, 2005
- Frontiers in nutrigenomics, proteomics, metabolomics and cancer preventionMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004
- SELECT: THE NEXT PROSTATE CANCER PREVENTION TRIALJournal of Urology, 2001
- A study of the mechanism of selenite-induced hypomethylated DNA and differentiation of Friend erythroleukemic cellsCarcinogenesis: Integrative Cancer Research, 1986
- Cancer mortality correlation studies-IV: Associations with dietary intakes and blood levels of certain trace elements, notably se-antagonistsBioinorganic Chemistry, 1977